文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

美国MRSA血流感染发病率趋势因菌株类型和医疗暴露而异(2005-2013)

Trends in Incidence of Methicillin-resistant Staphylococcus aureus Bloodstream Infections Differ by Strain Type and Healthcare Exposure, United States, 2005-2013.
PubMed 文献 · Clin Infect Dis · 2020-01-01

研究基于美国5个CDC Emerging Infections Program监测点2005-2013年的人群监测数据,按菌株类型和医疗暴露分类分析侵袭性MRSA血流感染发病率趋势。结果显示USA100发病率显著下降,而USA300在社区相关和医疗相关社区发病血流感染中未见显著变化,提示需加强社区USA300 MRSA血流感染的预防。

要点

  • USA100血流感染发病率在医院发病和医疗相关社区发病中显著下降。
  • USA300医院发病血流感染发病率下降,但社区相关和医疗相关社区发病无显著变化。
  • 注射吸毒者侵袭性MRSA为USA300的可能性更高(aOR 4.58)。

核心结论

  • MRSA血流感染发病率下降主要归因于USA100血流感染发病率的减少。
  • 需预防社区USA300 MRSA血流感染以进一步降低MRSA血流感染负担。

研究设计与样本

  • 基于美国5个CDC Emerging Infections Program监测点2005-2013年的人群监测,收集侵袭性MRSA分离株。
  • 按菌株类型和医疗暴露的流行病学分类分层计算每10万人口血流感染发病率。
  • 通过logistic回归比较2013年侵袭性USA100与USA300病例特征。

主要发现

  • 2005至2013年,USA100医院发病血流感染发病率从6.1降至0.9/10万人(P < .0001)。
  • USA100医疗相关社区发病血流感染发病率从10.7降至4.9/10万人(P < .0001)。
  • USA300医院发病血流感染发病率从1.5降至0.6/10万人(P < .0001)。
  • USA300医疗相关社区发病血流感染发病率从3.9降至3.3/10万人(P = .05),无显著变化。
  • USA300社区相关血流感染发病率从2.5降至2.4/10万人(P = .19),无显著变化。

关键数值与推荐

  • 侵袭性MRSA为USA300的可能性随年龄增长而降低(aOR 0.97/年,95%CI .96-.98)。
  • 既往住院患者侵袭性MRSA为USA300的可能性较低(aOR 0.36,95%CI .24-.54)。
  • 有中心静脉导管患者侵袭性MRSA为USA300的可能性较低(aOR 0.44,95%CI .27-.74)。
  • 注射吸毒者侵袭性MRSA为USA300的可能性较高(aOR 4.58,95%CI 1.16-17.95)。

临床怎么用

  • 应持续监测MRSA血流感染菌株类型以评估预防效果。
  • 社区USA300 MRSA血流感染的预防需针对注射吸毒者等人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous reports suggested that US methicillin-resistant Staphylococcus aureus (MRSA) strain epidemiology has changed since the rise of USA300 MRSA. We describe invasive MRSA trends by strain type. METHODS: Data came from 5 Centers for Disease Control and Prevention Emerging Infections Program sites conducting population-based surveillance and collecting isolates for invasive MRSA (ie, from normally sterile body sites), 2005-2013. MRSA bloodstream infection (BSI) incidence per 100 000 population was stratified by strain type and epidemiologic classification of healthcare exposures. Invasive USA100 vs USA300 case characteristics from 2013 were compared through logistic regression. RESULTS: From 2005 to 2013, USA100 incidence decreased most notably for hospital-onset (6.1 vs 0.9/100 000 persons, P < .0001) and healthcare-associated, community-onset (10.7 vs 4.9/100 000 persons, P < .0001) BSIs. USA300 incidence for hospital-onset BSIs also decreased (1.5 vs 0.6/100 000 persons, P < .0001). However, USA300 incidence did not significantly change for healthcare-associated, community-onset (3.9 vs 3.3/100 000 persons, P = .05) or community-associated BSIs (2.5 vs 2.4/100 000 persons, P = .19). Invasive MRSA was less likely to be USA300 in patients who were older (adjusted odds ratio [aOR], 0.97 per year [95% confidence interval {CI}, .96-.98]), previously hospitalized (aOR, 0.36 [95% CI, .24-.54]), or had central lines (aOR, 0.44 [95% CI, .27-.74]), and associated with USA300 in people who inject drugs (aOR, 4.58 [95% CI, 1.16-17.95]). CONCLUSIONS: Most of the decline in MRSA BSIs was from decreases in USA100 BSI incidence. Prevention of USA300 MRSA BSIs in the community will be needed to further reduce burden from MRSA BSIs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. See I, Mu Y, Albrecht V, et al. Trends in Incidence of Methicillin-resistant Staphylococcus aureus Bloodstream Infections Differ by Strain Type and Healthcare Exposure, United States, 2005-2013. Clin Infect Dis. 2020. PMID: 30801635. doi:10.1093/cid/ciz158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。